Abeona Therapeutics Stock News

Abeona Therapeutics (NASDAQ:ABEO) had its price target cut by HC Wainwright from $5.00 to $4.00 in a research report sent to investors on Monday, The Fly reports. They currently have a buy rating on the biopharmaceutical companys stock. A number of other research analysts have also recently issued reports on ABEO. Cantor Fitzgerald reissued an []

Abeona Therapeutics Inc. (ABEO) with the stream of -3.57% also noticed, India Armada Acquisition Corp. I (AACIW) encountered a rapid change of -3.83% in the last hour of trading session. The post Is This Just A Random Move? Abeona Therapeutics Inc. (NASDAQ:ABEO), Armada Acquisition Corp. I (NASDAQ:AACIW) appeared first on Stocks Equity .

The trading price of Abeona Therapeutics Inc. (NASDAQ:ABEO) closed lower on Tuesday, November 23, closing at $0.75, -4.03% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

In todays recent session, 0.52 million shares of the Abeona Therapeutics Inc. (NASDAQ:ABEO) have been traded, and its beta is 1.39. Most recently the companys share price was $0.78, and it changed around $0.0 or 0.66% from the last close, which brings the market valuation of the company to $82.03M. ABEO at last check was Stock Performance And Outlook Of Abeona Therapeutics Inc. (NASDAQ: ABEO) Read More »

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Synlogic Presents Positive Phase 2 Data For Synthetic Biologic Treatment In Inherited Metabolic Disord

NextPlay Technologies, Inc. (NXTP) with the stream of -3.98% also noticed, India Abeona Therapeutics Inc. (ABEO) encountered a rapid change of 6.63% in the last hour of Monday’s trading session. … The post Valuing Stock Using Ratios and Multiples: NextPlay Technologies, Inc. (NASDAQ:NXTP), Abeona Therapeutics Inc. (NASDAQ:ABEO) appeared first on Stocks Equity .

Geode Capital Management LLC reduced its stake in shares of Abeona Therapeutics Inc (NASDAQ:ABEO) by 40.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 657,021 shares of the biopharmaceutical companys stock after selling 452,168 shares during the quarter. Geode []

Zacks Investment Research upgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a hold rating to a buy rating in a report issued on Thursday, Zacks.com reports. Zacks Investment Research currently has $1.00 price target on the biopharmaceutical companys stock. According to Zacks, Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products []

Cantor Fitzgerald restated their overweight rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a research report report published on Thursday morning, Zacks.com reports. ABEO has been the topic of a number of other research reports. HC Wainwright reiterated a buy rating and set a $5.00 price target on shares of Abeona Therapeutics in a report []

Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reportin

Abeona Therapeutics (ABEO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts i

Abeona Therapeutics Inc. (NASDAQ:ABEO) price on Thursday, November 18, fall -9.76% below its previous days close as a downside momentum from buyers pushed the stocks value to $0.77. A look at the stocks price movement, the close in the last trading session was $0.85, moving within a range at $0.7343 and $0.865. The beta value New Outlook On Abeona Therapeutics Inc. Read More »

Abeona Therapeutics (ABEO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts i

Abeona Therapeutics Inc (NASDAQ:ABEO) Analysts at SVB Leerink boosted their Q4 2021 earnings per share estimates for Abeona Therapeutics in a research report issued on Monday, November 15th. SVB Leerink analyst M. Foroohar now expects that the biopharmaceutical company will post earnings of ($0.07) per share for the quarter, up from their previous forecast []

NEW YORK and CLEVELAND, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced its sponsorship of the second a